Fig. 1. Schlafen12 expression correlates with survival in triple negative breast cancer. A) Survival analysis of publicly available data set of cohorts of patients with triple negative breast cancer shows that SLFN12 mRNA expression correlates with relapse free survival (http://kmplot.com/analysis/; n=255, p<0.01). B) Survival analysis shows that Schlafen12 mRNA expression does not correlate with relapse free survival in patients with breast cancers expressing estrogen and progesterone receptors (http://kmplot.com/analysis/; n=559, p=0.19). C) Higher SLFN12 mRNA expression correlated with favorable Scarff Bloom and Richardson grade (http://bcgenex.centregauducheau.fr/, n=3627, p<0.0001). D) Higher SLFN12 mRNA expression correlated with favorable Nottingham Prognostic Index in breast cancer (http://bcgenex.centregauducheau.fr/, n=3114, p<0.0001). E) RNAseq analysis of publicly available data (https://www.ebi.ac.uk/gxa/home) of patients with breast cancers demonstrates that SLFN12 mRNA expression is reduced in breast cancer tissue vs. normal breast tissue or adjacent benign stroma. F) Representative images of Schlafen12 immunohistolabeling (brown stain) demonstrate reduced SLFN12 labeling intensity in triple negative breast cancer tissue (Ia, III) vs. benign tissue (Ib, II), (n=13, 200x).